^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Esophageal Cancer

    Related cancers:
    20h
    Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors (clinicaltrials.gov)
    P1, N=160, Recruiting, SystImmune Inc. | N=120 --> 160
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability) • FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • CLDN18 (Claudin 18) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    PD-L1 expression • KRAS mutation • MSI-H/dMMR • HER-2 overexpression • BRAF mutation • HER-2 mutation • IDH1 mutation • CLDN18.2 expression • FGFR2 mutation • FGFR2 fusion • IDH mutation + NTRK fusion • NTRK fusion
    21h
    MAGMAP: Magnetic Sentinel Lymph Node Mapping in Upper Gastro-Intestinal Cancer: A Feasibility Clinical Investigation (clinicaltrials.gov)
    P=N/A, N=60, Active, not recruiting, Ferronova Pty Ltd | Recruiting --> Active, not recruiting | Trial completion date: Feb 2029 --> May 2029 | Trial primary completion date: Feb 2026 --> May 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    1d
    CRUKD/20/001: A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1 (clinicaltrials.gov)
    P1/2, N=15, Suspended, Cancer Research UK | Trial completion date: Mar 2029 --> Oct 2026
    Trial completion date • Checkpoint inhibition • First-in-human
    |
    PD-L1 (Programmed death ligand 1) • MAGEA3 (MAGE Family Member A3)
    |
    VTP-600
    1d
    POP-UP: a Single-arm, Two-cohort Study: an 8-week Trimodal Pre-habilitation Program for Patients With Pancreatic Ductal Adenocarcinoma and Oesogastric (clinicaltrials.gov)
    P=N/A, N=9, Active, not recruiting, GERCOR - Multidisciplinary Oncology Cooperative Group | Recruiting --> Active, not recruiting | N=72 --> 9
    Enrollment closed • Enrollment change
    1d
    Impact of immunochemotherapy administration sequence on overall survival in advanced esophageal and gastric cancers: a propensity score-matched multicenter analysis. (PubMed, Cancer Immunol Immunother)
    This study suggests that administering chemotherapy prior to immunotherapy appears to improve OS in patients with advanced EC and GC, particularly when initiated as first-line treatment. These findings highlight the need for further research into biomarkers and personalized treatment strategies to enhance patient outcomes.
    Clinical • Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    3d
    Predictive impact of systemic inflammation and tertiary lymphoid structures on pathological complete response in neoadjuvant-treated advanced esophageal squamous carcinoma patients. (PubMed, Pathol Res Pract)
    Systemic/local immune profiles are related to pCR. A decreased SII+NLR independently predicts pCR, whereas different TLS features may be associated with pCR. Immune responses should be given attention to optimize treatment for advanced esophageal squamous carcinoma patients receiving preoperative treatment.
    Journal
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1)
    3d
    Discovery of novel 2,4-diarylaminopyrimidine derivatives as FAK inhibitors with potent anti-cancer potency. (PubMed, Future Med Chem)
    A series of derivatives (D1-D15) was designed and synthesized by incorporating a hydrazone unit into the TAE-226 scaffold...Mechanistically, compound D12 effectively suppressed FAK phosphorylation and downstream MAPK/ERK and AKT/mTOR signaling, leading to inhibition of colony formation, migration, cell cycle progression, and induction of apoptosis. Compound D12 is a novel FAK inhibitor with improved selectivity and potent antitumor activity, representing a promising lead candidate for cancer therapy.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    NVP-TAE226
    4d
    Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P2, N=126, Completed, Beijing Biostar Pharmaceuticals Co., Ltd. | Recruiting --> Completed | Trial completion date: Dec 2024 --> May 2025 | Trial primary completion date: Mar 2024 --> May 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    utidelone IV (UTD1)
    4d
    Efficacy and Safety oF FErric CarboxymalTose in Patients With Advanced Gastric Cancer(EFFECT-AGC) (clinicaltrials.gov)
    P3, N=330, Recruiting, Asan Medical Center | Trial completion date: Nov 2024 --> Nov 2026 | Trial primary completion date: Nov 2024 --> Nov 2026
    Trial completion date • Trial primary completion date
    4d
    A Study of Trastuzumab in Combination With Capecitabine and Cisplatin in Patients With Tissue HER2- But Serum HER2+ AGC (clinicaltrials.gov)
    P2, N=28, Completed, Asan Medical Center | Recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    cisplatin • capecitabine • Ontruzant (trastuzumab-dttb)
    4d
    Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection (clinicaltrials.gov)
    P=N/A, N=2000, Recruiting, Alliance for Clinical Trials in Oncology | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial primary completion date
    |
    MUC16 (Mucin 16, Cell Surface Associated)